E. Peruzzi
10 Papers
2 Citations
E. Peruzzi is an academic researcher. The author has contributed to research in topics: Circulating tumor cell & Medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
Rossana Roncato,Lorenzo Gerratana,L. Palmero,Sara Gagno,Ariana Soledad Poetto,E. Peruzzi,Martina Zanchetta,Bianca Posocco,Elena De Mattia,Giovanni Canil,M. Alberti,Marco Orleni,Giuseppe Toffoli,Fabio Puglisi,Erika Cecchin +14 more
TL;DR: In one patient, a CYP3A5*1/*3 genotype was found to be potentially responsible for more efficient drug metabolism and lower drug plasma concentration, which could be ultimately useful for increasing both the safety and efficacy profiles of CDKi treatment.
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
E. Peruzzi,Rossana Roncato,Elena De Mattia,Alessia Bignucolo,Jesse J. Swen,Henk-Jan Guchelaar,Giuseppe Toffoli,Erika Cecchin +7 more
TL;DR: The results of a large prospective randomized trial in Europe have provided the first evidence that prospective application of a preemptive pharmacogenomic test panel in clinical practice is feasible and yielded a 30% reduction in the risk of developing clinically relevant toxicities.
8
Use of the DEPArray platform to detect, isolate, and molecularly characterize pure tumor cells from peripheral blood samples enriched using the CellSearch system.
Gianni Medoro,Steven Gross,Nicolò Manaresi,M. Sergio,Francesca Fontana,Stefano Gianni,Alex Calanca,E. Peruzzi,M. Banzi,Giulio Signorini,Chandra Rao,Jaymala Patel,J. Karkera,G. Giorgini,M. Mata,Mark Connelly +15 more
TL;DR: DEPArray achieved 100% purity, eliminating all white blood cells (WBC), in the isolation of a mixed population of tumor cell lines downstream of CellSearch enrichment, enabling molecular profiling of pure tumor cells from whole blood spiked tumor cell Lines.
7
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
Alessia Bignucolo,Elena De Mattia,Rossana Roncato,E. Peruzzi,Lucia Scarabel,Maria Lydia D'andrea,Franca Sartor,Giulia Toffoli,Erika Cecchin +8 more
TL;DR: In this article , the authors describe the evolution of DPYD diagnostic activity at the National Cancer Institute, CRO-Aviano (Italy) over the last 10 years as a case example of a successful introduction of pharmacogenetic testing in clinical practice.
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer.
E. Peruzzi,Lorenzo Gerratana,Marcella Montico,Bianca Posocco,Serena Corsetti,Michele Bartoletti,Sara Gagno,Marco Orleni,Elena De Mattia,Massimo Baraldo,Erika Cecchin,Fabio Puglisi,Giuseppe Toffoli,Rossana Roncato +13 more
- 19 Sep 2023
TL;DR: Findings offer promising insights into the role of pharmacogenetic markers in CDKis safety profiles, potentially contributing to address the interindividual variability inCDKis responses.
4